WO2002011756A3 - Anti-plasmodium compositions and methods of use - Google Patents

Anti-plasmodium compositions and methods of use Download PDF

Info

Publication number
WO2002011756A3
WO2002011756A3 PCT/US2001/024725 US0124725W WO0211756A3 WO 2002011756 A3 WO2002011756 A3 WO 2002011756A3 US 0124725 W US0124725 W US 0124725W WO 0211756 A3 WO0211756 A3 WO 0211756A3
Authority
WO
WIPO (PCT)
Prior art keywords
falciparum
binding
methods
compositions
paralogues
Prior art date
Application number
PCT/US2001/024725
Other languages
French (fr)
Other versions
WO2002011756A2 (en
Inventor
David L Narum
Kim L Sim
Original Assignee
Entremed Inc
David L Narum
Kim L Sim
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Entremed Inc, David L Narum, Kim L Sim filed Critical Entremed Inc
Priority to AU2001281140A priority Critical patent/AU2001281140A1/en
Publication of WO2002011756A2 publication Critical patent/WO2002011756A2/en
Publication of WO2002011756A3 publication Critical patent/WO2002011756A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Compositions that inhibit the binding of Plasmodium falciparum to erythrocytes include a family of erythrocyte binding proteins (EBPs). The EBPs are paralogues of the P. falciparum binding protein EBA-175. The present invention includes peptides of the paralogues that prevent the binding of P. falciparum. Antibodies specific for each paralogue that also prevent the binding of P. falciparum are also included. Methods of the invention utilize the paralogues, antibodies thereof and peptide compositions for the diagnosis, prevention, and treatment of P. falciparum diseases such as malaria, as well as methods for the detection of P. falciparum in biological samples and culture media.
PCT/US2001/024725 2000-08-07 2001-08-07 Anti-plasmodium compositions and methods of use WO2002011756A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001281140A AU2001281140A1 (en) 2000-08-07 2001-08-07 Anti-plasmodium compositions and methods of use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22352500P 2000-08-07 2000-08-07
US60/223,525 2000-08-07

Publications (2)

Publication Number Publication Date
WO2002011756A2 WO2002011756A2 (en) 2002-02-14
WO2002011756A3 true WO2002011756A3 (en) 2003-01-09

Family

ID=22836887

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/024725 WO2002011756A2 (en) 2000-08-07 2001-08-07 Anti-plasmodium compositions and methods of use

Country Status (3)

Country Link
US (2) US20020127241A1 (en)
AU (1) AU2001281140A1 (en)
WO (1) WO2002011756A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002338238A1 (en) * 2001-04-02 2002-10-15 The Government Of The United States Of America, As Represented By The Secretary, Department Of Healt Plasmodium falciparum erythrocyte binding protein baebl for use as a vaccine
WO2006081308A2 (en) 2005-01-25 2006-08-03 The Johns Hopkins University Plasmodium diagnostic assay device
US8252293B2 (en) * 2006-09-14 2012-08-28 Nanyang Technological University Binding domain of Plasmodium reticulocyte binding proteins
US8703147B2 (en) * 2007-11-05 2014-04-22 The Walter And Eliza Hall Institute Of Medical Research Methods and compositions for treating and preventing malaria (2)
EP2328909B1 (en) * 2008-09-26 2013-10-23 The University of Hong Kong Human catechol-O-methyltransferase (COMT) assay
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
CN103282380B (en) 2010-08-10 2018-02-16 洛桑聚合联合学院 Erythrocyte binding therapeutic agent
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
CN103965318B (en) * 2013-01-28 2016-12-28 苏州偲聚生物材料有限公司 Polypeptide, the detection device comprising this polypeptide and detection kit
CN103965339B (en) * 2013-01-28 2016-09-28 苏州偲聚生物材料有限公司 Polypeptide, the detection device comprising this polypeptide and detection kit
CN103965315B (en) * 2013-01-28 2016-12-28 苏州偲聚生物材料有限公司 Polypeptide, the detection device comprising this polypeptide and detection kit
CN103965317B (en) * 2013-01-28 2016-09-28 苏州偲聚生物材料有限公司 Polypeptide, the detection device comprising this polypeptide and detection kit
CN103965319B (en) * 2013-01-28 2016-08-10 苏州偲聚生物材料有限公司 Polypeptide, the detection device comprising this polypeptide and detection kit
CN103965312B (en) * 2013-01-28 2016-08-10 苏州偲聚生物材料有限公司 Polypeptide, the detection device comprising this polypeptide and detection kit
CN103965316B (en) * 2013-01-28 2016-08-10 苏州偲聚生物材料有限公司 Polypeptide, the detection device comprising this polypeptide and detection kit
CN103965328B (en) * 2013-01-29 2016-09-28 苏州偲聚生物材料有限公司 Polypeptide, the detection device comprising this polypeptide and detection kit
CN103965330B (en) * 2013-01-29 2016-08-10 苏州偲聚生物材料有限公司 Polypeptide, the detection device comprising this polypeptide and detection kit
CN103965332B (en) * 2013-01-29 2016-08-10 苏州偲聚生物材料有限公司 Polypeptide, the detection device comprising this polypeptide and detection kit
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
EP3107563B1 (en) 2014-02-21 2021-04-07 Ecole Polytechnique Fédérale de Lausanne (EPFL) EPFL-TTO Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
EP3638296A1 (en) 2017-06-16 2020-04-22 The University Of Chicago Compositions and methods for inducing immune tolerance

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3817837A (en) * 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
DE69434221T2 (en) * 1993-09-10 2006-01-19 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Binding domains of Plasmodius vivax and Plasmodium falciparum erythrocyte binding proteins
US5993827A (en) * 1993-09-10 1999-11-30 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Binding domains from plasmodium vivax and plasmodium falciparum erythrocyte binding proteins
AU3395400A (en) 1999-03-04 2000-09-21 Entremed, Inc Anti-plasmodium compositions and methods of use
AU2002338238A1 (en) 2001-04-02 2002-10-15 The Government Of The United States Of America, As Represented By The Secretary, Department Of Healt Plasmodium falciparum erythrocyte binding protein baebl for use as a vaccine

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] EBI; 15 March 1999 (1999-03-15), "Plasmodium falciparum genome sequence", XP002207624, Database accession no. AL049180 *
KAPPE STEFAN H I ET AL: "Erythrocyte binding protein homologues of rodent malaria parasites.", MOLECULAR AND BIOCHEMICAL PARASITOLOGY, vol. 89, no. 1, 1997, pages 137 - 148, XP002207621, ISSN: 0166-6851 *
MAYER D C GHISLAINE ET AL: "Characterization of a Plasmodium falciparum erythrocyte-binding protein paralogous to EBA-175.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 98, no. 9, 24 April 2001 (2001-04-24), April 24, 2001, pages 5222 - 5227, XP002207622, ISSN: 0027-8424 *
PETERSON DAVID S ET AL: "Isolation of multiple sequences from the Plasmodium falciparum genome that encode conserved domains homologous to those in erythocyte-binding proteins.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 92, no. 15, 1995, 1995, pages 7100 - 7104, XP002207620, ISSN: 0027-8424 *
TRIGLIA TONY ET AL: "An EBA175 homologue which is transcribed but not translated in erythrocytic stages of Plasmodium falciparum.", MOLECULAR AND BIOCHEMICAL PARASITOLOGY, vol. 116, no. 1, August 2001 (2001-08-01), pages 55 - 63, XP002207623, ISSN: 0166-6851 *

Also Published As

Publication number Publication date
US7303751B2 (en) 2007-12-04
WO2002011756A2 (en) 2002-02-14
US20020127241A1 (en) 2002-09-12
US20060153881A1 (en) 2006-07-13
AU2001281140A1 (en) 2002-02-18

Similar Documents

Publication Publication Date Title
WO2002011756A3 (en) Anti-plasmodium compositions and methods of use
Chen et al. Molecular aspects of severe malaria
WO2004018649A3 (en) Monoclonal antibodies and complementarity-determining regions binding to ebola glycoprotein
Rodrı́guez et al. Plasmodium vivax MSP-1 peptides have high specific binding activity to human reticulocytes
Urquiza et al. Plasmodium falciparum AMA-1 erythrocyte binding peptides implicate AMA-1 as erythrocyte binding protein
Tonelli et al. Selection of binding targets in parasites using phage-display and aptamer libraries in vivo and in vitro
ATE263243T1 (en) PROTECTIVE ANTIBODIES-INDUCING ANTIGENS FROM PLASMODIUM FALCIPARUM
Oeuvray et al. A novel merozoite surface antigen of Plasmodium falciparum (MSP-3) identified by cellular-antibody cooperative mechanism antigenicity and biological activity of antibodies
WO1995007353A3 (en) Binding domains from plasmodium vivax and plasmodium falciparum erythrocyte binding proteins
Fried et al. Mass spectrometric analysis of Plasmodium falciparum erythrocyte membrane protein‐1 variants expressed by placental malaria parasites
WO1996040766A3 (en) Binding domains from plasmodium vivax and plasmodium falciparum erythrocyte binding proteins
WO2004030622A3 (en) Method of isolation and self-assembly of small protein particles from blood and other biological materials
EP0753009B1 (en) Malaria peptides
WO2001042277A3 (en) Complementary peptide ligands generated from the human genome
US10344082B2 (en) Anti-parasitic complexes
Ocampo et al. Plasmodium vivax Duffy binding protein peptides specifically bind to reticulocytes
WO2003026700A3 (en) Compositions for transporting antibodies through the blood brain barrier and their use for diagnosing or treating central nervous system diseases
CA2089660A1 (en) New peptides and their use
WO2000052056A3 (en) Anti-plasmodium compositions and methods of use
Silva et al. Effects of the angiotensin II Ala-scan analogs in erythrocytic cycle of Plasmodium falciparum (in vitro) and Plasmodium gallinaceum (ex vivo)
WO2001092321A3 (en) Proteins involved in cytoadhesion of plasmodium falciparum ring-stage-infected erythrocytes
Gaur et al. Molecular basis of erythrocyte invasion by Plasmodium merozoites
Garraud et al. Different Plasmodium falciparum recombinant MSP119 antigens differ in their capacities to stimulate in vitro peripheral blood T lymphocytes in individuals from various endemic areas
WO2004052914A8 (en) Compositions and methods for inhibiting malaria protease falcipain-2
Omelianczyk Role of STEVOR and its interacting partners in parasite virulence

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP